Source comparison
ARA290 vs Erythropoietin: Key Structural Differences
Amino Acid Length 165 amino acids 11 amino acids ARA290 lacks the erythropoietic domain entirely Receptor Target Homodimeric EPO receptor (EPOR-EPOR) Heterodimeric innate repair receptor (EPOR-βc) No haematopoietic stimulation with ARA290 Primary Action Erythr
This comparison does not assign a generated winner or score.
- Amino Acid Length
- 165 amino acids
- 11 amino acids
- ARA290 lacks the erythropoietic domain entirely
- Receptor Target
- Homodimeric EPO receptor (EPOR-EPOR)
- Heterodimeric innate repair receptor (EPOR-βc)
- No haematopoietic stimulation with ARA290
- Primary Action
- Erythropoiesis (red blood cell production)
- Tissue protection, anti-inflammatory signalling
- ARA290 applicable where EPO's haematocrit elevation is contraindicated
- Half-Life (subcutaneous)
- 20–24 hours
- 4–6 hours
- ARA290 requires more frequent dosing
- Thrombotic Risk
- Elevated with chronic use (polycythemia)
- None observed in Phase 2 trials
- Safer profile for patients with cardiovascular comorbidities
- FDA Status
- Approved (Epogen, Procrit for anaemia)
- Investigational (no approved indication)
- ARA290 available only as research compound